JP2015530404A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530404A5
JP2015530404A5 JP2015532965A JP2015532965A JP2015530404A5 JP 2015530404 A5 JP2015530404 A5 JP 2015530404A5 JP 2015532965 A JP2015532965 A JP 2015532965A JP 2015532965 A JP2015532965 A JP 2015532965A JP 2015530404 A5 JP2015530404 A5 JP 2015530404A5
Authority
JP
Japan
Prior art keywords
peptide
active ingredient
conjugate
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530404A (ja
JP6510410B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2013/008445 external-priority patent/WO2014046481A1/ko
Publication of JP2015530404A publication Critical patent/JP2015530404A/ja
Publication of JP2015530404A5 publication Critical patent/JP2015530404A5/ja
Application granted granted Critical
Publication of JP6510410B2 publication Critical patent/JP6510410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532965A 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 Active JP6510410B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR20120104144 2012-09-19
KR10-2012-0104144 2012-09-19
KR20120109216 2012-09-28
KR10-2012-0109216 2012-09-28
KR10-2013-0017169 2013-02-18
KR20130017169 2013-02-18
KR10-2013-0017046 2013-02-18
KR20130017046 2013-02-18
PCT/KR2013/008445 WO2014046481A1 (ko) 2012-09-19 2013-09-17 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Publications (3)

Publication Number Publication Date
JP2015530404A JP2015530404A (ja) 2015-10-15
JP2015530404A5 true JP2015530404A5 (enExample) 2016-11-10
JP6510410B2 JP6510410B2 (ja) 2019-05-08

Family

ID=50341702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532965A Active JP6510410B2 (ja) 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Country Status (8)

Country Link
US (1) US9631184B2 (enExample)
EP (1) EP2899199B1 (enExample)
JP (1) JP6510410B2 (enExample)
KR (1) KR102201430B1 (enExample)
CN (3) CN110028554B (enExample)
ES (1) ES2743919T3 (enExample)
TW (1) TWI598441B (enExample)
WO (1) WO2014046481A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
CN104661672B (zh) 2012-05-11 2017-03-08 珍白斯凯尔有限公司 用于预防或治疗败血症的组合物
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
JP6352923B2 (ja) 2012-09-19 2018-07-04 ジェムバックス アンド カエル カンパニー,リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
ES2758451T3 (es) 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
EP2987497B1 (en) 2013-04-19 2018-12-26 Gemvax & Kael Co., Ltd. Composition for treating and preventing ischemic damage
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー,リミティド ホルモン分泌調節剤、及びそれを含む組成物
JP6574175B2 (ja) * 2013-07-12 2019-09-11 ジェムバックス アンド カエル カンパニー,リミティド 細胞透過性ペプチド、及びそれを含むコンジュゲート
KR101691479B1 (ko) 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
KR102694658B1 (ko) 2013-11-22 2024-08-14 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー,リミティド 前立腺癌治療用組成物
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー,リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
KR20250073577A (ko) 2015-05-26 2025-05-27 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20180064434A (ko) * 2015-11-03 2018-06-14 주식회사 젬백스앤카엘 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR101661912B1 (ko) 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021225344A1 (ko) * 2020-05-08 2021-11-11 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
DE69739497D1 (de) * 1996-10-01 2009-08-27 Geron Corp Menschlische Telomerase katalytische Untereinheit
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2007097561A1 (en) 2006-02-20 2007-08-30 Ewha University - Industry Collaboration Foundation Peptide having cell membrane penetrating activity
KR20090103957A (ko) * 2007-01-29 2009-10-01 주식회사 프로셀제약 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
HUE030984T2 (en) * 2008-06-16 2017-06-28 Mediolanum Farm S P A Antitumor immunotherapy
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101169030B1 (ko) * 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
CN108383894A (zh) * 2010-02-16 2018-08-10 阿尔特公司 多肽及其应用
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
ES2758451T3 (es) 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
JP6352923B2 (ja) 2012-09-19 2018-07-04 ジェムバックス アンド カエル カンパニー,リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR101778244B1 (ko) * 2014-05-13 2017-09-26 한양대학교 산학협력단 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법

Similar Documents

Publication Publication Date Title
JP2015530404A5 (enExample)
JP2016500648A5 (enExample)
JP2016500513A5 (enExample)
JP2015530358A5 (enExample)
Kang et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma
JP2024073589A (ja) エキソソームを標的化する方法
JP6789823B2 (ja) 両末端peg化インテグリン結合性ペプチドおよびその使用方法
JP2011037872A5 (enExample)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2015522264A5 (enExample)
JP2014526881A5 (enExample)
RU2015102027A (ru) Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов
Noguchi et al. Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery
JP2012529293A5 (enExample)
CN110114367A (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
CN103788211B (zh) 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物
JP2016526021A5 (enExample)
EP3925973A1 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
Wong et al. The therapeutic anticancer potential of marine-derived bioactive peptides: a highlight on pardaxin
US10597426B2 (en) Polypeptide compound and preparation method and use thereof
US20180244724A1 (en) Polypeptide compound and preparation method and use thereof
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
Britton Engineering Functionalized Biomaterials From Coiled-Coil Protein Designs
JP2020501521A5 (enExample)
JP6479331B2 (ja) 脊髄組織標的化ペプチド及びその利用